120 results about "Cell replacement" patented technology

The present invention provides cell populations that are enriched for mesendoderm and mesoderm, and cell populations that are enriched for endoderm. The cell populations of the invention are useful for generating cells for cell replacement therapy.

The present invention relates to utrons, RNA molecules which contain promoter regulatory motif(s) and DNA analogs thereof and DNA molecules that can be transcribed to produce the foregoing. In particular, the invention provides gene promoter suppressing nucleic acids which suppress transcription from a promoter of interest. In a preferred embodiment, the invention provides the TSU gene, nucleotide sequences of the TSU gene and RNA, as well as fragments, homologs and derivatives thereof. Methods of isolating TSU genes are also provided. Therapeutic and diagnostic methods and pharmaceutical compositions are also provided. In particular, the invention relates to methods for cell replacement therapy, gene therapy or organ transplantation wherein TSU nucleic acids suppress MHC class I and II gene expression, thus preventing immuno-rejection of non-autologous cells or organs. The invention also provides methods for treatment of diseases or disorders by suppression of MHC class I, MHC class II, ICAM-1, B7-1, B7-2, and/or Fc gamma R expression by provision of TSU function.

The present invention discloses and describes pluripotent homozygous stem (HS) cells, and methods and materials for making same. The present invention also provides methods for differentiation of HS cells into progenitor (multipotent) cells or other desired cells, groups of cells or tissues. Further, the applications of the HS cells disclosed herein, include (but are not limited to) the diagnosis and treatment of various diseases (for example, genetic diseases, neurodegenerative diseases, endocrine-related disorders and cancer), traumatic injuries, cosmetic or therapeutic transplantation, gene therapy and cell replacement therapy.

The present invention provides cell populations that are enriched for mesendoderm and mesoderm, and cell populations that are enriched for endoderm. The cell populations of the invention are useful for generating cells for cell replacement therapy.

An objective of the present invention is to overcome a problem that there is an inverse relationship between the decellularization rate and the strength of tissue. This problem was solved by immersing tissue in a solution containing a non-micellar amphipathic molecule (e.g., a 1,2-epoxide polymer). Thus, the present invention provides decellularized tissue, in which the cell survival rate of the tissue is less than a level at which calcification or an immune reaction is elicited in an organism and the tissue damage rate of the tissue is suppressed to a level which permits clinical applications. Tissue prepared by the above-described treatment preferably retains a certain level of tissue strength. Further, the tissue of the present invention has an effect of performing cell replacement.

The present invention relates to methods of using granulocyte colony stimulating factor (G-CSF) polypeptide, alone and in conjunction with stromal cell derived factor (SDF-1) polypeptide, to increase the mobilization of c-Kit+ stem cells in the blood, bone marrow, tissue, heart or other organs for the subsequent production of embryoid body-like cell clusters. These embryoid body-like cell clusters can be used for cell replacement therapy, for the treatment of cardiac myopathy and other diseases and disorders, and for screening agents that drive or inhibit differentiation and proliferation.

The present disclosure is directed to improved methods for efficiently producing neuroprogenitor cells and differentiated neural cells such as dopaminergic neurons and serotonergic neurons from pluripotent stem cells, for example human embryonic stem cells. Using the disclosed methods, cell populations containing a high proportion of cells positive for tyrosine hydroxylase, a specific marker for dopaminergic neurons, have been isolated. The neuroprogenitor cells and terminally differentiated cells of the present disclosure can be generated in large quantities, and therefore may serve as an excellent source for cell replacement therapy in neurological disorders such as Parkinson's disease.

The present invention discloses and describes pluripotent homozygous stem (HS) cells, and methods and materials for making same. The present invention also provides methods for differentiation of HS cells into progenitor (multipotent) cells or other desired cells, groups of cells or tissues. Further, the applications of the HS cells disclosed herein, include (but are not limited to) the diagnosis and treatment of various diseases (for example, genetic diseases, neurodegenerative diseases, endocrine-related disorders and cancer), traumatic injuries, cosmetic or therapeutic transplantation, gene therapy and cell replacement therapy.

The embodiment of the invention provides a cell replacement method and a cell replacement device. The method comprises the following steps of: determining a target cell for cell replacement as a micro cell, wherein the cell replacement comprises cell reselection or cell handover; determining the mobile state or mobile speed of UE (user equipment); and carrying out cell replacement judgment aiming at the target cell according to the moving state or the moving speed of the UE. According to the embodiment of the invention, during the process of carrying out the cell replacement judgment aiming at the micro cell, the moving state or the moving speed of the UE is considered so as to reduce unnecessary cell replacement aiming at the micro cell, thus the system burden and the UE power consumption which are caused by frequent cell replacement are lowered.

It is necessary to periodically replace a cell of an implantable-type cardiac pacemaker device, which causes suffering to a patient as often as a cell is replaced. Thus, it is an object of the present invention to dispense with cell replacement of the cardiac pacemaker device. A cardiac pacemaker device of the present invention has an antenna and a battery built-in, and an electric power is transmitted to the built-in antenna from outside a body by an electromagnetic wave to store the electric power in the battery. With the use of the electric power stored in the battery, a main body of the pacemaker device can operate. If necessary, the electric power can be supplied wirelessly from outside and a surgery for exchanging a cell becomes unnecessary; therefore, a patient's suffering can be relieved.

The present invention is directed to methods for readily propagating somatic hair follicle stem cells or melanocyte stem cells. The methods comprise enhancing guanine nucleotide (GNP) biosynthesis, thereby expanding guanine nucleotide pools. This in turn conditionally suppresses asymmetric cell kinetics in the explanted cells. The methods of the invention include pharmacological methods and genetic methods. For example, the resulting cultured somatic hair follicle stem cells can be used for a variety of applications including cell replacement therapies such as hair transplants, gene therapies, and tissue engineering applications, such as the generation of artificial skin and skin regeneration strategies including skin grafts.

The invention discloses a method for configuring a wireless network. According to the method, private network cells are set in an express way region, and the private network cells are covered by a dedicated frequency point region; a neighbouring region relationship is configured for the private network cells and public network cells in the site region of an express way; the neighbouring region relationship between the private network cells and the public network cells is not configured in an express way region without an intersection. According to the method, the defects of frequent cell replacement, low access success rate and conversation quality declining of high-speed mobile terminal equipment in the existing network are solved. By virtue of the method, the replacement frequency of the equipment among the different cells can be reduced, the switching and reselection paths of the equipment in case of high-speed movement are ensured well, and the communication quality is improved. The applications of a radio resource management algorithm, a switching and reselection policy and network parameter values dedicated to high-speed scenes are promoted, thus the quality of the whole network is improved better.

The invention relates to a recombinant adenovirus vector for efficiently inducing a pluripotent stem cell (PS cell) and method for inducing the PS cell by using the recombinant adenovirus vector. The recombinant adenovirus vector is characterized in that the fiber genes therein are B subgroup adenovirus fiber genes, and an Sox2 gene expression cassette and an Oct4 gene expression cassette are connected within the recombinant adenovirus vector in an operating way. The terminally differentiated cell or the adult stem cell of the mammal, particularly the human is infected in vitro, the Oct4 genes and the Sox2 genes are expressed in an ectopic way, and the terminally differentiated cell or the adult stem cell of the mammal, particularly the human can be induced into the PS cell efficiently and rapidly under the synergistic effect of adjusting the epigenetic-inheritance small-molecular medicament. The PS cell of the human can be used for the cell replacement therapy to treat diseases, and the PS cell of the mammal can be used for preparing the transgenic animal model and the animal disease model.

Provided is a composition for treating nerve damage-related diseases. The composition includes a human umbilical cord blood-derived mesenchymal stem cell as an active ingredient. The mesenchymal stem cell isolated and incubated from the human umbilical cord blood migrates to an injured area to be differentiated into a nerve cell or a neuroglial cell at the time of in vivo transplantation. Thus, the mesenchymal stem cell and a composition including the same can be effectively used in cell replacement therapy and gene therapy for treating diseases caused by nerve damage including a stroke, Parkinson's disease, Alzheimer's disease, Pick's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic central nervous system disease and a spinal cord injury.

he present invention is of a method of dynamically generating human embryoid bodies which can be used for generating lineage specific cells and cell lines. Specifically, the present invention can be used to generate ESC-differentiated cells for cell-replacement therapy.

The invention discloses an electric vehicle energy supplying method. The method comprises the following steps: a, detecting an electric vehicle model to be supplied by a model detection system to acquire model information; b, selecting a vehicle positioning program corresponding to the model information from a plurality of pre-saved vehicle positioning programs by a control system according to the detected model information, and controlling the vehicle positioning system for vehicle positioning by the vehicle positioning program; and c, controlling a dynamic cell replacing system by the control system to select a dynamic cell with dynamic cell type information matched with the model information for dynamic cell replacement. The invention also discloses an electric vehicle energy supply system. The method and the system can realize energy supply for various different types of electric vehicles only by a replacement platform.

The present disclosure is directed to improved methods for efficiently producing neuroprogenitor cells and differentiated neural cells such as GABAergic neurons from pluripotent stem cells, for example embryonic stem cells. Using the disclosed methods, cell populations containing a high proportion of GABAergic neurons have been isolated. The neuroprogenitor cells and terminally differentiated cells of the present disclosure can be generated in large quantities, and therefore may serve as an excellent source for cell replacement therapy in neurodegenerative disorders and neuronal diseases such as stroke, ischemia, epilepsy, and Huntington's disease.

The invention relates to the unmanned plane electric power inspection field and particularly relates to an automatic unmanned plane cell replacement device for electric power inspection and a control method thereof. The device comprises a cell chamber arranged at a bottom portion of an unmanned plane, undercarriages arranged at two sides of the cell chamber and a cell seat used for replacing the unmanned plane cell. The automatic unmanned plane cell replacement device is advantaged in that automatic cell replacement in an unmanned plane inspection process can be realized, the charging time in the unmanned plane inspection process can be saved, a conductive slot is internally arranged in the unmanned plane, cell replacement without power failure can be realized, and a problem of data or program loss during start of the unmanned plane after power failure can be avoided. The invention further provides a control method based on the automatic unmanned plane cell replacement device, and the method is applied to automatic control on the automatic unmanned plane cell replacement device.

A layout method is provided, adaptable to place cell on a chip. Firstly, a chip area is assigned for a floor plan. A global reservation deployment process is then performed to define a plurality of room units to be uniformly distributed on the chip area. Cells are placed on the chip based on the floor plan. The chip area is categorized into at least a high frequency region and a low frequency region according to operation frequencies of the placed cells thereon. A frequency based reservation deployment process is then performed to move one or more room units distributed in the low frequency region toward the high frequency region. A local cell replacement process, a routing and timing analysis are performed. If hotspots are induced, room units around the hotspots are redistributed, and then the steps of local cell replacement, routing and timing analysis are repeated.